Phaarmasia
109.00
-109.00(-100.00%)
Market Cap₹74.40 Cr
PE Ratio4.19
IndustryHealthcare
Company Performance:
1D-100.00%
1M-100.00%
6M-100.00%
1Y-100.00%
5Y-100.00%
View Company Insightsright
More news about Phaarmasia
13Aug 25
Phaarmasia Limited Reports Q1 FY2026 Results: Revenue Up 26.6% QoQ, Net Profit Rebounds
Phaarmasia Limited announced Q1 FY2026 results with revenue from operations at Rs 687.36 lakhs, up 26.6% QoQ. The company reported a net profit of Rs 27.02 lakhs, compared to a loss in the previous quarter. Total income reached Rs 718.88 lakhs, with total expenses at Rs 687.58 lakhs. EPS for the quarter was Rs 0.40. The company maintained its paid-up equity share capital at Rs 682.70 lakhs and reported zero outstanding loans or debt securities.
 no imag found
11Aug 25
Phaarmasia Limited Reports Q1 FY2026 Results: Revenue Declines 17.1% YoY, Shows Sequential Improvement
Phaarmasia Limited's Q1 FY2026 results show a 17.1% year-over-year revenue decline to Rs. 687.36 lakhs, but a 26.6% sequential increase from Q4 FY2025. Net profit marginally decreased by 2.2% YoY to Rs. 27.02 lakhs. The company returned to profitability after a loss in the previous quarter. Total expenses decreased by 16.1% YoY, helping to mitigate the impact of lower revenue. EPS remained stable at Rs. 0.40.
 no imag found
Phaarmasia
109.00
-109.00
(-100.00%)
1 Year Returns:-100.00%
Industry Peers
Sun Pharmaceutical
1,618.50
(-0.12%)
Divis Laboratories
6,320.00
(-0.65%)
Torrent Pharmaceuticals
4,110.40
(-0.17%)
Dr Reddys Laboratories
1,313.00
(-0.31%)
Lupin
2,298.00
(+0.08%)
Cipla
1,296.00
(+0.08%)
Mankind Pharma
2,266.00
(-0.06%)
Zydus Life Science
926.95
(-0.05%)
Aurobindo Pharma
1,414.00
(+0.01%)
Glenmark Pharmaceuticals
2,287.00
(-0.54%)